Literature DB >> 12895192

Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil.

B Shum1, S B Duffull, P J Taylor, S E Tett.   

Abstract

AIM: To develop a population pharmacokinetic model for mycophenolic acid in adult kidney transplant recipients, quantifying average population pharmacokinetic parameter values, and between- and within-subject variability and to evaluate the influence of covariates on the pharmacokinetic variability.
METHODS: Pharmacokinetic data for mycophenolic acid and covariate information were previously available from 22 patients who underwent kidney transplantation at the Princess Alexandra Hospital. All patients received mycophenolate mofetil 1 g orally twice daily. A total of 557 concentration-time points were available. Data were analysed using the first-order method in NONMEM (version 5 level 1.1) using the G77 FORTRAN compiler.
RESULTS: The best base model was a two-compartment model with a lag time (apparent oral clearance was 27 l h(-1), and apparent volume of the central compartment 98 l). There was visual evidence of complex absorption and time-dependent clearance processes, but they could not be successfully modelled in this study. Weight was investigated as a covariate, but no significant relationship was determined.
CONCLUSIONS: The complexity in determining the pharmacokinetics of mycophenolic acid is currently underestimated. More complex pharmacokinetic models, though not supported by the limited data collected for this study, may prove useful in the future. The large between-subject and between-occasion variability and the possibility of nonlinear processes associated with the pharmacokinetics of mycophenolic acid raise questions about the value of the use of therapeutic monitoring and limited sampling strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895192      PMCID: PMC1884287          DOI: 10.1046/j.1365-2125.2003.01863.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

2.  A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients.

Authors:  P I Pillans; R J Rigby; P Kubler; C Willis; P Salm; S E Tett; P J Taylor
Journal:  Clin Biochem       Date:  2001-02       Impact factor: 3.281

Review 3.  Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.

Authors:  L M Shaw; M Korecka; D DeNofrio; K L Brayman
Journal:  Clin Biochem       Date:  2001-02       Impact factor: 3.281

4.  Limited sampling strategy for mycophenolic acid area under the curve.

Authors:  G Filler; I Mai
Journal:  Ther Drug Monit       Date:  2000-04       Impact factor: 3.681

Review 5.  The use of mycophenolate mofetil in transplant recipients.

Authors:  T S Mele; P F Halloran
Journal:  Immunopharmacology       Date:  2000-05

6.  The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients.

Authors:  A G Johnson; R J Rigby; P J Taylor; C E Jones; J Allen; K Franzen; M C Falk; D Nicol
Journal:  Clin Pharmacol Ther       Date:  1999-11       Impact factor: 6.875

7.  Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.

Authors:  T van Gelder; J Klupp; M J Barten; U Christians; R E Morris
Journal:  Ther Drug Monit       Date:  2001-04       Impact factor: 3.681

8.  Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.

Authors:  M Mourad; J Malaise; D Chaib Eddour; M De Meyer; J König; R Schepers; J P Squifflet; P Wallemacq
Journal:  Clin Chem       Date:  2001       Impact factor: 8.327

9.  Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients.

Authors:  C Willis; P J Taylor; P Salm; S E Tett; P I Pillans
Journal:  Ther Drug Monit       Date:  2000-10       Impact factor: 3.681

10.  Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients.

Authors:  G I Hübner; R Eismann; W Sziegoleit
Journal:  Ther Drug Monit       Date:  1999-10       Impact factor: 3.681

View more
  26 in total

1.  Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.

Authors:  Wai-Johnn Sam; Melanie S Joy
Journal:  Ther Drug Monit       Date:  2010-10       Impact factor: 3.681

Review 2.  Clinical mycophenolic acid monitoring in liver transplant recipients.

Authors:  Hao Chen; Bing Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Time-dependent clearance of mycophenolic acid in renal transplant recipients.

Authors:  Reinier M van Hest; Teun van Gelder; René Bouw; Timothy Goggin; Robert Gordon; Richard D Mamelok; Ron A Mathot
Journal:  Br J Clin Pharmacol       Date:  2007-01-03       Impact factor: 4.335

5.  Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation.

Authors:  Christine E Staatz; Stephen B Duffull; Bryce Kiberd; Albert D Fraser; Susan E Tett
Journal:  Eur J Clin Pharmacol       Date:  2005-07-28       Impact factor: 2.953

Review 6.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

7.  Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.

Authors:  H Li; D E Mager; B M Sandmaier; D G Maloney; M J Bemer; J S McCune
Journal:  J Clin Pharmacol       Date:  2013-02-04       Impact factor: 3.126

8.  Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients.

Authors:  Yan Rong; Patrick Mayo; Mary H H Ensom; Tony K L Kiang
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

9.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.

Authors:  Bronwyn A Atcheson; Paul J Taylor; David W Mudge; David W Johnson; Carmel M Hawley; Scott B Campbell; Nicole M Isbel; Peter I Pillans; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.